Ever since it was discovered that endothelial cells line lymphatic vessels, investigators have been working on unraveling the mechanisms that control the growth of this distinctive endothelium and its role in normal physiology and human disease. Recent technological advances have ushered in a new era of "omics" research on the lymphatic system. Research on the genome, transcriptome, proteome, and metabolome of lymphatics has increased our understanding of the biology of the lymphatic vasculature. Here, we introduce the context-lymphatic "systemomics," then briefly review some of the latest advances in research on tumor-associated lymphatic vessels highlighting several "omic" studies that have shed light on mechanisms controlling the growth and function of tumor-associated lymphatic vessels. We conclude by returning, with unanswered questions, to the larger context of cancer and the lymphatic system as a vasculature, circulation, route of entry and transport, and control center of the immune network.
In this focused review of lymphangiogenesis, we will first put lymphangiogenesis in context, i.e., a growth and development process within the lymphatic system-its vessels, lymph nodes, extravascular extracellular fluid circulation, route of entry and transport, and immune network. As we examine this process in relation to cancer development and spread, we will return to this "systemomics" perspective to face challenges and unanswered questions that need ultimately to be explored as identified and yet to be identified molecules and signaling pathways in lymphangiogenesis are elucidated before we can reach fuller understanding and attempt to target this specific process in cancer therapy.
Historically (reviewed in [1, 2] ), lymphvasculogenesis/ lymphangiogenesis, although the term was not used until the 1980s, arose as a topic of intense interest in the early 1900s surrounding the controversy over the centripetal vs. centrifugal embryologic development of the lymphatic vasculature. The process was subsequently studied as a response to lymphatic obstruction and also inflammation. At around the same time, parallel progress was taking place in early understanding of the immune system, participating immunocytes (lymphocytes were not inert and Metchnikoff's reticuloendothelial system was an acknowledged player), lymph nodal structure and function, and how these worked together in producing immune responses. Distinctive ultrastructure of lymphatic vessels particularly endothelial lining was delineated [3] and further dissected on a structure-functional level while entry and transport of microbes, cells, lipids, and foreign particles in the lymphatic system was explored. With the introduction of conventional oil contrast lymphography Presented at the 7th International Cancer Metastasis Symposium in San Francisco, CA from April 20 to 22, 2017 (http://www.cance rmeta stasi s.org).
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in the 1950s [4] along with other imaging modalities to follow events dynamically within the living human lymphatic system, no longer could the system be viewed as "lymph nodes held together by strings". Dynamic in vivo lymphatic system imaging meticulously documented normal as well as abnormal lymphatic and lymph nodal structure and function in different cancers/lymphomas and was even used for staging and therapeutic decisions including as a route for selective endolymphatic chemotherapy. Characteristic lymphographic abnormalities were observed for the first time in a wide variety of congenital-sporadic and hereditary-and acquired lymphatic disorders including those involving disturbed lymphatic growth and development [4] . The concept and selective imaging of sentinel nodes in cancer spread would emerge decades later [5] . Beginning in the 1960s, thoracic duct cannulation and lymph drainage in human subjects opened up a window into the pathophysiology of a variety of diseases, most notably, hepatic cirrhosis [6] and congestive heart failure [7] , and also in organ transplantation, and cancer. With the convergence of these landmark events leading to a "systemomic" and holistic view of the lymphatic system, the discipline of lymphology-the study of lymphatics, lymph, lymph nodes, and lymphocytes in health and disease-was founded in 1966.
In the 1700s and early 1800s, cancer was viewed as arising in tissue fluid or "lymph" until its cellular nature was later postulated initially as endothelium ("endothelial theory"), embryonic cells ("blastema theory") and finally pinpointed as parenchymal cells by Virchow [8, 9] . Still, it was well recognized that cancers spread to lymph nodes via draining lymphatic channels (lymphogenous spread), and treatment approaches became directed at progressively more radical efforts to halt this route of spread. When thinking changed in the 1970s and newly developed drugs became available to target hematogenous spread, chemotherapy emerged as a predominant treatment modality [10] . Also in the l970s, angiogenesis (more appropriately termed "hemangiogenesis") became a topic of increasing interest because of its potential to modulate cancer growth and spread [11] . Shortly thereafter, lymphatic endothelium was isolated for the first time in tissue culture [12] , and "lymphangiogenesis" in vitro was described along with categorization of human "lymphangiogenic disorders" including tumors of lymphatic vessels ("lymphangiotumorigenesis") [13] . As late as 1997 [14, 15] , there remained controversy as to whether "tumor lymphangiogenesis" existed, let alone was a factor in cancer spread.
Meanwhile, in the late 1980s and early 1990s, specific (blood) vascular endothelial growth factors and their cognate receptors were discovered and molecularly characterized-the first, VEGF-A [16] , previously identified as Vascular Permeability Factor in carcinomatous ascites [17] , and subsequently the angiopoietin family. VEGF seemed key to hemangiogenesis and cancer blood supply and survival, and accordingly, the search for angiogenesis-inhibitors intensified. Later, discovery of other members of the VEGF family-namely VEGF-C [18] and VEGF-D [19] -more specific for lymphatic growth together with lymphatic-specific biomarker stains [LYVE-1 and podoplanin (D2-40)] ushered in the era of molecular lymphology and with it, expanded understanding of lymphvascular genomics, proteomics, and other "omics" in lymphatic development and disease. Since 2000, a succession of human "lymphangiogenesis" genes, among them VEGFR3, FOXC2, SOX18, CCBE1, GJC2 (connexin 43), PTPN14, GATA2, KIF11, VEGFC, GJA1 (connexin 47)-have been identified, where disease-causing mutations lead to specific rare lymphedema-angiodysplasia syndromes (LE-AD) [20] . Many other gene mutations have been associated with LE-AD syndromes in experimental models. Some of these genes are associated with syndromic malignancies or otherwise implicated in cancer. Thus, the universe of molecules and networks-predicted and unexpected-involved in normal and abnormal lymphangiogenesis and lymphatic function has greatly expanded raising questions of their role, interactions, and feedback loops in a variety of diseases including cancer. Related controversy persists around the relative importance and even the nature of lymphatic vs. blood vessel invasion; interendothelial vs. intra/transendothelial passage of tumor cells; lymphogenous vs. hematogenous spread within and from the primary tumor and metastatic sites, particularly regional lymph nodes and central lymphatics [21] [22] [23] [24] [25] .
Lymphangiogenesis, tumor lymphangiogenesis, and cancer

Lymphangiogenesis facilitates metastasis to lymph nodes
The discovery of lymphatic growth factors enabled researchers to delve more deeply into the role lymphatics serve in the tumor microenvironment. VEGF-C and VEGF-D are growth factors that induce the formation of new lymphatic vessels. In 2001, three key studies showed that tumor lymphangiogenesis facilitates metastasis to lymph nodes in mice [26] [27] [28] . Subsequent studies revealed that inhibition of VEGF-C could prevent tumor lymphangiogenesis and metastasis in mice [29] [30] [31] . These observations prompted researchers to determine whether there was a relationship between VEGF-C expression in human tumors and the density of tumor-associated lymphatics or lymph node status. Indeed, many studies have found that VEGF-C expression in human tumors correlates with either intratumoral or peritumoral lymphatic vessel density [31] [32] [33] [34] [35] and lymph node status [32, 33, [36] [37] [38] [39] .
As mentioned earlier, blood vessels can also serve as an escape route for cancer cells. Indeed, blood vessel invasion in primary tumors can serve as a prognostic indicator for many different cancers [25, 40, 41] . Recently, intravital imaging of experimental models of cancer has provided insight into the mechanism of intravasation of cancer cells. Time-lapse imaging of blood vessels, macrophages, and cancer cells in MMTV-PyMT tumors revealed that cancer cells preferentially intravasate at sites where perivascular macrophages are located [42] . This tripartite structure of endothelial cells, macrophages, and cancer cells has been termed TMEM (tumor microenvironment of metastasis). Importantly, TMEM structures have been found in human tumor samples and correlate with the development of distant organ metastases [43] . It remains unclear as to whether macrophages facilitate cancer cell invasion of lymphatic vessels. Additionally, the mechanisms that dictate whether a cancer cell invades a blood vessel or a lymphatic vessel remain unknown.
Molecular profiling of lymphangiogenic cancer cells
Although the link between lymphangiogenesis and metastasis has received strong support, the precise molecular mechanisms driving tumor lymphangiogenesis remain poorly understood. This gap in knowledge exists, in part, because most animal research on tumor lymphangiogenesis involves cancer cell lines that have been engineered to overexpress a lymphatic growth factor. To fill this gap in knowledge, a screen was performed with molecularly annotated cancer cell lines to identify cell lines that were capable of inducing lymphangiogenesis on their own [44] . This screen revealed that Calu-1, H1993, HCC461, HCC827, and H2122 non-small cell lung cancer (NSCLC) cells induce lymphangiogenesis, whereas Calu-3, H1155, H1975, and H2073 NSCLC cells do not induce lymphangiogenesis [44] . Genome-wide mRNA expression data for the cell lines revealed that only 17 genes were differentially expressed between the lymphangiogenic group and the non-lymphangiogenic group [44] . Importantly, VEGF-C was part of this gene signature and was approximately 50-fold higher in the lymphangiogenic group than the non-lymphangiogenic group [44] . Subsequent experiments revealed that forced-expression of VEGF-C by a non-lymphangiogenic cell line stimulated lymphangiogenesis, whereas knockdown of VEGF-C in a lymphangiogenic cell line inhibited lymphangiogenesis [44] . These data show, in an unbiased manner, that VEGF-C is a driver of tumor lymphangiogenesis in experimental NSCLC.
Lymphangiogenesis at pre-metastatic niches
Lymphangiogenesis occurs in primary tumors and in tumor-draining lymph nodes [45, 46] . Lymph node lymphangiogenesis takes place prior to the arrival of cancer cells [45, 46] . The precise function of lymph node lymphangiogenesis remains unclear, but it could prime the lymph node (the "soil") for the ensuing cancer cells (the "seeds"). Recently, a Vegfr3-luciferase reporter mouse, termed MetAlert, was used to study the formation of premetastatic niches [47] . The investigators found an increase in bioluminescence at distal sites before metastasis [47] . By analyzing the proteome of tumor-secreted exosomes, the investigators identified midkine as a candidate driver of pre-metastatic niches [47] . Loss-of-function experiments revealed that inhibition of midkine decreased bioluminescence at distal sites and inhibited metastasis to lymph nodes [47] . Conversely, gain-of-function experiments revealed that overexpression of midkine increased bioluminescence at distal sites and metastasis to lymph nodes [47] . Future work with the Met-Alert mouse may shed further light on the molecular mechanisms controlling the formation of pre-metastatic niches and the function they serve in metastasis.
Lymph node metastases potentially give rise to distant metastases
A subject of controversy in the field is whether lymph node metastases give rise to distant metastases. Lymph node metastases could function as indicators of metastasis or as incubators for metastasis [48] . Next generation sequencing techniques have recently been applied to characterize the step-wise progression of cancer in experimental models of cancer. One study on the evolution of cancer in a mouse model of small cell lung carcinoma (SCLC) reported that, in at least one instance, a liver metastasis arose from a lymph node metastasis [49] . This study provided initial experimental evidence that a lymph node metastasis can spread to a distant site. Recent animal studies have provided additional evidence that lymph node metastases can spawn distant metastases. In one study, the investigators were able to trace the fate of cancer cells that stably expressed the photoconvertible protein Dendra2 [50] . They found that photoconverted cancer cells could enter lymph node blood vessels and form lung metastases [50] . A separate study found that cancer cells microinfused into lymph nodes could metastasize to the lung via lymph node blood vessels [51] . High endothelial venules (HEVs) are highly permeable sinudoidal like vessels, quite different from typical blood vessels, uniquely suited for lymphocyte trafficking and therefore, perhaps also for tumor cell "trafficking" [52] . Despite these recent advances, the extent to which distant metastases originate from lymph node metastases remains unclear.
Lymphatic endothelial cells (LECs) and tumor immunity
A growing number of reports have focused on the immunological functions of tumor-associated lymphatic vessels. In addition to transporting cancer cells, lymphatic vessels transport antigens [53] . Interestingly, LECs in lymph nodes have the ability to scavenge and present antigens to T cells [54] . This interaction causes PDL1 on LECs to interact with PD1 on T cells and triggers the inhibition of T cells [55] [56] [57] . Tumor-associated lymphatics have also been suggested to inhibit the activity of T cells by upregulating the expression of PDL1 [56] . Recently, it was reported that VEGF-C expression by B16 melanoma cells protects tumors against anti-tumor immunity [54] . However, it was later reported that lymphangiogenic B16 tumors were more sensitive to immune therapy than non-lymphangiogenic B16 tumors [58] . These contradictory findings reveal that there is still much to be learned in this emerging area of research. Continued research in this area will further define the impact of lymphatic vessels on anti-tumor immunity. Additionally, approaches such as single-cell RNA-Seq could be used to further delineate the crosstalk between LECs and immune cells and identify molecular vulnerabilities that could be exploited to promote anti-tumor immunity.
Unanswered questions
Over the past 50 years, substantial progress has been made in the field of lymphology. Despite this progress, many unanswered questions still exist regarding the biology of the lymphatic system, lymphangiogenesis, and specifically tumor-associated lymphatic vessels. The differences in gene expression between normal and tumor-associated lymphatics have not been extensively investigated, the crosstalk between LECs and immune cells is poorly understood, and the extent to which lymph node metastases give rise to distant metastases remains unclear. Importantly, continued "omics" research in the field will explore currently unanswered questions and identify new ones thereby increasing our understanding of the biology of tumor-associated lymphatics in the context of the entire lymphatic system and could lead to new therapeutic strategies to inhibit metastasis or revitalize anti-tumor immunity in cancer patients.
In the context of lymphatic systemomics and its relation to cancer development and spread, some of the unanswered questions that need exploration encompass:
Lymphatic vasculature
How do normal and disordered changes in lymphatic vasculature and lymphatic endothelium influence development, proliferation, invasion and metastasis of cancer and certain "benign metastasizing" neoplasms of the lymphatic vasculature? What are the KEY control mechanisms/molecular basis and interactions in these processes-e.g., lymphvasculogenesis, lymphangiogenesis, lymphvascular mimicry, lymphatic permeability, lymphatic contractility, lymphaticvenous shunting, lymphatic obstruction/reflux, lymphendothelial transdifferentiation to other cell types, EMT-MET? What is the role of "vascular mimicry" [59] (tumor celllined channels) and contribution to metastasis?
Lymph circulation
Which among the many proposed altered interstitially acting and circulating substances/mediators in local interstitial fluid (tumor microenvironment), afferent/efferent regional, and central lymph preponderantly alone or together influence the progression of human cancer-pre-metastatic niches and organ-specific metastases? What role do heightened blood vascular permeability (VPF), (lymph)edema formation, altered ECM mechanical properties, heightened tissue pressure, lymphatic obstruction/sequelae play in producing, heightening, and mediating these influences in the primary, pre-metastatic, and metastatic sites-e.g., VEGFs, angiopoietins, other growth factors; various cytokines/chemokines, integrins, cadherins, MMPs, lipids/fatty acids, hyaluronan oligosaccharides, exosomes, adrenomedullin, tumor neoantigens, etc.? How do they work together?
Lymphatic route of entry and transport
What events [and specific cellular (e.g., dendritic cells), molecular mediators] take place at portal of entry (skin/ mucosa) or during transport that might (pre)determine effect of carcinogens, foreign antigens, cancer-causing or protective microbes, etc. on cancer development and spread? How can agents/techniques be improved for selective dynamic lymphatic/lymph node/tumor imaging and targeted intralymphatic therapy? What is relative role of hematogenous vs. lymphogenous spread in specific cancers and of the thoracic duct as a route-can quantitation be made now that liquid biopsy is available?
Lymphatic/"lymphoid" (immune) system-cells, organs, their contents, and trafficking
What are the key determinants of whether the immune system protects or enhances development and spread of specific cancers? What "lymphosystemomic" events take place in
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sentinel and non-sentinel lymph nodes before and during cancer spread and which are the key players in these events? What is the optimum composition, route of administration, dosing, timing, etc. of anti-cancer vaccines (for lymphatic entry/processing)? How can immunotherapy (and combination therapy) be optimized to take advantage of this knowledge to personalize, predict, co-stimulate anti-cancer efficacy, and reduce toxicity?
Final reflections
The explosion of molecular lymphology has also, perhaps unintentionally been accompanied by a turning away from the more systemic, holistic, and historical view of the lymphatic system and its role in cancer and specifically how to promote its beneficial functions and to control its harmful ones. The narrowing of focus to one known molecule, family of molecules, or putative single all encompassing signaling pathway, or even a specific physiologic process such as lymphangiogenesis to date has had generally disappointing applications in the clinical treatment of cancer such as with VEGF inhibitors. On the other hand, recent success of immunotherapy, a modality decades in development, in select highly aggressive cancers such as metastatic melanoma and small cell lung cancers now necessitates a return to "lymphatic systemomics" to understand and treat cancer with this modality let alone to understand the immune system physiology and pathophysiology beyond its detailed molecular players and signaling pathways. Indeed, scientists and clinicians in the field of cancer, are themselves returning to "systemomics"-an "omic" Lederberg omitted in his original list but doubtless would have included now [60] -to incorporate what has been learned from the more reductionist molecular "omics" approaches to the underlying systemomic vision of precision/personalized medicine in cancer care and to make the ultimate treatment-driving correlation between host/cancer genotype and clinical phenotype of both in individual patients i.e., "putting the patient back together" [61] . Ironically, this task may entail reexploring the hidden truths and insights in the various historic theories of cancer development and spread and relationships to the tumor microenvironment and macroenvironment [62] .
